CoChat

Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes

Open access
D'Alessio, David A., Denney, Amanda M., Hermiller, Linda M., Prigeon, Ronald L., Martin, Julie M., Tharp, William G., Saylan, Monica Liqueros, He, YanLing, Dunning, Beth E., Foley, James E., Pratley, Richard E. · 2009 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of action, DPP-4 inhibitors improve glucose tolerance after meals by increasing insulin and reducing glucagon levels in the plasma. However, DPP-4 inhibitors also reduce fasting blood glucose, an unexpected effect because circulating levels of active GIP and GLP-1 are low in the postabsorptive state. Objective: The objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function. Design: We conducted a randomized, double-blind, placebo-controlled trial. Setting: The study was performed in General Clinical Research Centers at two University Hospitals. Subjects: Forty-one subjects with T2DM were treated with metformin or diet, having good glycemic control with glycosylated hemoglobin values of 6.2–7.5%. Intervention: Subjects were treated with vildagliptin (50 mg twice daily) or placebo for 3 months, followed by a 2-wk washout. Major Outcome Measure: We measured insulin secretion in response to iv glucose and arginine before and after treatment and after drug washout. Results: There were small and comparable reductions in glycosylated hemoglobin in both groups over 3 months. Vildagliptin increased fasting GLP-1 levels in subjects taking metformin, but not those managed with diet, and raised active GIP levels slightly. DPP-4 inhibitor treatment improved the acute insulin and C-peptide responses to glucose (50 and 100% respectively; P < 0.05) and increased the slope of the C-peptide response to glucose (33%; P = 0.023). Conclusion: Vildagliptin improves islet function in T2DM under fasting conditions. This suggests that DPP-4 inhibition has metabolic benefits in addition to enhancing meal-induced GLP-1 and GIP activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-1135

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Bergman, 1979, Am J Physiol, 236, E667

Cited by

See all 99

Metadata

Authors
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., & Pratley, R. E.
Affiliations
  • Department of Medicine (D.A.D., A.M.D., L.M.H.), University of Cincinnati and Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio 45267
  • Cincinnati VA Medical Center (US)
  • University of Maryland, Baltimore (US)
  • University of Vermont (US)
  • Clinical Research and Development (M.L.S.), Novartis Pharmaceuticals, East Hanover, New Jersey 07936
  • Clinical Research and Development (Y.H., J.E.F.), Novartis Pharmaceuticals, Cambridge, Massachusetts 02139
  • Pharmawrite (B.E.D.), Princeton New Jersey 08540
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2009-01-01
Volume
94
Issue
1
Pages
81-88
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1967477040
Cited by
99
References
39
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 7 · 2013: 8 · 2012: 7
FWCI
7.72
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK57900, R01DK057900)
  • National Center for Research Resources (M01 RR00109, M01RR000109, M01 RR 0808)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
vildagliptin, DPP-4 inhibitors, type 2 diabetes, insulin secretion, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretins, C-peptide response, metformin, arginine stimulation, HbA1c
MeSH terms
Vildagliptin, Adamantane, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Fasting, Glycated Hemoglobin, Humans, Islets of Langerhans, Middle Aged, Nitriles, Pyrrolidines, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/jc.2008-1135
The paper
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., & Pratley, R. E. (2009). Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-1135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.